CAS 1026753-54-7

Imatinib Impurity 18

CAS : 1026753-54-7

Formule : C₂₉H₃₁N₇O

Couleur et forme : Off-White Solid

Masse moléculaire : 493.62

Ref: 4Z-I-0923

4-[(4-Methyl-1-piperazinyl)methyl]-N-[3-methyl-4-[[4-(3- pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide

CAS : 1026753-54-7

Couleur et forme : Neat

Ref: 86-MM3566.17

Imatinib para-Diaminomethylbenzene

Produit contrôlé

CAS : 1026753-54-7

Applications Imatinib para-Diaminomethylbenzene is an impurity of Imatinib, a tyrosine kinase inhibitor. It is a COVID19-related research product.
References Schindler, T., et al.: Science, 289, 1938 (2000); Drucker, B.J., et al.: N. Engl. J. Med., 344, 1031 (2001)

Formule : C₂₉H₃₁N₇O

Couleur et forme : Off-White

Masse moléculaire : 493.60

Ref: TR-I267975

Imatinib Para-diaminomethylbenzene Impurity Hydrochloride Salt

Produit contrôlé

CAS : 1026753-54-7

Applications Imatinib impurity. It is a COVID19-related research product.

Formule : C₂₉H₃₁N₇OxHCl

Couleur et forme : Neat

Masse moléculaire : 493.603646

Ref: TR-I267995

Imatinib para-diaminomethylbenzene

CAS : 1026753-54-7

Imatinib is a kinase inhibitor that inhibits the kinase activity of tyrosine-protein phosphatase receptor (c-Abl) and platelet-derived growth factor receptor (PDGFR), which are both involved in tumor cell proliferation. Imatinib has been shown to be effective in treating leukemia and other types of cancer, as well as regulating the production of cytokines and protein tyrosine phosphatases. It is also being studied for use in Alzheimer's disease. Imatinib has selectivity for c-Abl over PDGFR, which makes it an attractive drug candidate for cancer therapy.

Formule : C₂₉H₃₁N₇O

Degré de pureté : Min. 95%

Masse moléculaire : 493.6 g/mol

Ref: 3D-BRB75354

Imatinib Para-PPA Impurity

CAS : 1026753-54-7

Formule : C₂₉H₃₁N₇O

Masse moléculaire : 493.6

Ref: ST-EA-CP-I5043